Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised controlled non-inferiority study of dose reduction and withdrawal strategies of adalimumab and etanercept in rheumatoid arthritis: Saving costs at what expense?

Trial Profile

Randomised controlled non-inferiority study of dose reduction and withdrawal strategies of adalimumab and etanercept in rheumatoid arthritis: Saving costs at what expense?

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms DRESS
  • Most Recent Events

    • 12 Jun 2017 3-year long term data (results from the extension phase of the study, n=172) published in the Annals of the Rheumatic Diseases.
    • 22 Jul 2015 Status changed from active, no longer recruiting to completed.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top